Extended Data Fig. 4: Circulating GP73 traffics to the liver and binds to the hepatocyte surface.
From: GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia
a, In vivo imaging of live anesthetized mice 30 min after i.v. injection of rmGP73-Cy7 or free Cy7 (n = 4). b, Tissue GP73 accumulation in Fig. 3a was measured as the photon intensity. P = 0.0129 for rmGP73-Cy7 versus free Cy7 (pancreas), P = 0.0019 for rmGP73-Cy7 versus free Cy7 (brain), P < 0.0001 for rmGP73-Cy7 versus free Cy7 (spleen, kidney and liver) by two-tailed Student’s t-tests. c, In vivo imaging of various organs from mice 1 h or 19 h after rmGP73-Cy7 or free Cy7 injection. Two representative images from four mice are shown. d, Liver GP73 accumulation in mice 1 h or 19 h after rmGP73-Cy7 or free Cy7 injection. P < 0.0001 for 1 h versus 19 h (rmGP73-Cy7) by one-way ANOVA followed by Bonferroni’s post hoc test. e, The level of biotin on the hepatocyte surface upon incubation of H22 cells with increasing concentrations of rhGP73-biotin or rmGP73-biotin with (nonspecific binding) or without (total binding) 100-fold excess recombinant GP73 in the medium was measured using a colorimetric assay. Specific binding (shown in red) was calculated as the difference between the two curves. Animal and cell-based studies were performed independently at least three times with comparable results. The data were the means ± SEMs. *P < 0.05; **P < 0.01; ***P < 0.001.
